We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Phreesia (PHR) Q1 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Phreesia (PHR - Free Report) is expected to reveal quarterly loss of $0.13 per share, indicating an increase of 62.9% compared to the year-ago period. Analysts forecast revenues of $114.69 million, representing an increase of 13.3% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Phreesia metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Revenus- Subscription and related services' will reach $52.43 million. The estimate points to a change of +12.2% from the year-ago quarter.
The consensus among analysts is that 'Revenus- Network solutions' will reach $33.40 million. The estimate indicates a year-over-year change of +21.8%.
Analysts forecast 'Revenus- Payment processing fees' to reach $28.87 million. The estimate points to a change of +6.7% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Average healthcare services Clients' of 4,373. Compared to the current estimate, the company reported 4,065 in the same quarter of the previous year.
Analysts' assessment points toward 'Average revenue per healthcare services client' reaching $18.65 million. The estimate is in contrast to the year-ago figure of $18.24 million.
According to the collective judgment of analysts, 'Patient payment volume' should come in at $1.25 billion. The estimate is in contrast to the year-ago figure of $1.17 billion.
Phreesia shares have witnessed a change of -2.8% in the past month, in contrast to the Zacks S&P 500 composite's +8.2% move. With a Zacks Rank #3 (Hold), PHR is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gear Up for Phreesia (PHR) Q1 Earnings: Wall Street Estimates for Key Metrics
The upcoming report from Phreesia (PHR - Free Report) is expected to reveal quarterly loss of $0.13 per share, indicating an increase of 62.9% compared to the year-ago period. Analysts forecast revenues of $114.69 million, representing an increase of 13.3% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Phreesia metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Revenus- Subscription and related services' will reach $52.43 million. The estimate points to a change of +12.2% from the year-ago quarter.
The consensus among analysts is that 'Revenus- Network solutions' will reach $33.40 million. The estimate indicates a year-over-year change of +21.8%.
Analysts forecast 'Revenus- Payment processing fees' to reach $28.87 million. The estimate points to a change of +6.7% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Average healthcare services Clients' of 4,373. Compared to the current estimate, the company reported 4,065 in the same quarter of the previous year.
Analysts' assessment points toward 'Average revenue per healthcare services client' reaching $18.65 million. The estimate is in contrast to the year-ago figure of $18.24 million.
According to the collective judgment of analysts, 'Patient payment volume' should come in at $1.25 billion. The estimate is in contrast to the year-ago figure of $1.17 billion.
View all Key Company Metrics for Phreesia here>>>
Phreesia shares have witnessed a change of -2.8% in the past month, in contrast to the Zacks S&P 500 composite's +8.2% move. With a Zacks Rank #3 (Hold), PHR is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>